© 2021 MJH Life Sciences and HCPLive. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive. All rights reserved.
January 20, 2021
About half of patients experienced adverse events, and two-thirds of those events were likely related to inflammatory bowel disease medications.
January 13, 2021
Researchers suggest bolstering beneficial gut species depleted in COVID-19 could mitigate severe disease.
It’s possible that C diff could be a marker for frailty in geriatric patients.
January 11, 2021
The negative effects of the pandemic may disrupt efforts to eradicate HBV as a public health threat by 2030.
January 09, 2021
Using piperacillin/tazobactam increases the risk for acute kidney injury, and this risk can be exacerbated by concurrent vancomycin.
January 07, 2021
New phase 3 data show the IL-23 inhibitor is associated with clinical remission and endoscopic response.
Anastomotic leak can increase morbidity, mortality, and length and cost of hospital stays.
January 06, 2021
January 01, 2021
There is not currently an FDA approved treatment for NASH.
December 31, 2020
Investigators compared the 2010 and 2017 IDSA and SHEA guidelines to identify which better predicted C diff patients’ severity and mortality.